National regimen-specific consent forms for systemic anti-cancer therapy (SACT)


Session type:


Rena Chauhan1,Janine Mansi1,Dulcie Ireland2
1Guy's and St. Thomas' NHS Foundation Trust,2Cancer Research UK



The 2009 National Chemotherapy Advisory Group (NCAG) report included recommendations regarding consent for chemotherapy and proposed actions in relation to consent and information.  Guy’s and St. Thomas NHS Foundation Trust (GSTFT) developed SACT regimen-specific consent forms to address the recommendations, enabling high quality standardised information from clinician to patient, no omissions of information, and a tool for teaching and training; these forms are used in South East London.  The practice of consent for SACT varies in the UK, with some chemotherapy providers using generic Department of Health forms and others using specific documentation.  The National Chemotherapy Board commissioned a project to develop a library of national SACT regimen-specific consent forms.


Cancer Research UK (CRUK) were approached for support; they awarded a grant to GSTFT to host the project.  The template for the national consent form, based on the existing GSTFT forms, was developed with input from cancer patients, consultants, pharmacists and nurses.  A procedure for the production, validation and publication of the forms was developed and piloted.  National regimen-specific consent forms for breast cancer regimens were produced.  A guidance document was developed to support the process of consent for SACT.  A webpage on the CRUK website was developed to host the forms and associated documents.


The National Chemotherapy Board recommends the use of standardised SACT regimen-specific consent forms in the UK.  The guidance document and consent forms for breast cancer regimens were published in May 2016 on the CRUK website, and are available for all chemotherapy providers in the UK.  Forms for the remaining tumour sites will be published throughout 2016.


Adoption of the national SACT regimen-specific consent forms and working to the principles outlined in the guidance document will support clinicians to ensure that patients receiving SACT in the UK are fully informed when consenting to treatment.